A systematic analysis of FDA-approved anticancer drugs

doi:10.1186/s12918-017-0464-7

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 国家新药筛选中心

	A systematic analysis of FDA-approved anticancer drugs
	Sun, Jingchun 1; Wei, Qiang 1; Zhou, Yubo2 ; Wang, Jingqi 1; Liu, Qi 3; Xu, Hua 1
刊名	BMC SYSTEMS BIOLOGY
	2017-10-03
卷号	11 页码:27-43
关键词	Anticancer drugs Drug-cancer network Cancer-drug-target network Drug repurposing
ISSN号	1752-0509
DOI	10.1186/s12918-017-0464-7
文献子类	Article
英文摘要	Background: The discovery of novel anticancer drugs is critical for the pharmaceutical research and development, and patient treatment. Repurposing existing drugs that may have unanticipated effects as potential candidates is one way to meet this important goal. Systematic investigation of efficient anticancer drugs could provide valuable insights into trends in the discovery of anticancer drugs, which may contribute to the systematic discovery of new anticancer drugs. Results: In this study, we collected and analyzed 150 anticancer drugs approved by the US Food and Drug Administration (FDA). Based on drug mechanism of action, these agents are divided into two groups: 61 cytotoxicbased drugs and 89 target-based drugs. We found that in the recent years, the proportion of targeted agents tended to be increasing, and the targeted drugs tended to be delivered as signal drugs. For 89 target-based drugs, we collected 102 effect-mediating drug targets in the human genome and found that most targets located on the plasma membrane and most of them belonged to the enzyme, especially tyrosine kinase. From above 150 drugs, we built a drug-cancer network, which contained 183 nodes (150 drugs and 33 cancer types) and 248 drug-cancer associations. The network indicated that the cytotoxic drugs tended to be used to treat more cancer types than targeted drugs. From 89 targeted drugs, we built a cancer-drug-target network, which contained 214 nodes (23 cancer types, 89 drugs, and 102 targets) and 313 edges (118 drug-cancer associations and 195 drug-target associations). Starting from the network, we discovered 133 novel drug-cancer associations among 52 drugs and 16 cancer types by applying the common target-based approach. Most novel drug-cancer associations (116, 87%) are supported by at least one clinical trial study. Conclusions: In this study, we provided a comprehensive data source, including anticancer drugs and their targets and performed a detailed analysis in term of historical tendency and networks. Its application to identify novel drug-cancer associations demonstrated that the data collected in this study is promising to serve as a fundamental for anticancer drug repurposing and development.
资助项目	Cancer Prevention & Research Institute of Texas[CPRIT R1307]
WOS关键词	NETWORK PHARMACOLOGY ; CANCER DRUGS ; LUNG-CANCER ; DISCOVERY ; PARADIGM ; THERAPEUTICS ; INFORMATION ; COMBINATION ; ONCOLOGY ; THERAPY
WOS研究方向	Mathematical & Computational Biology
语种	英语
出版者	BIOMED CENTRAL LTD
WOS记录号	WOS:000412891600004
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/272458]
专题	国家新药筛选中心
通讯作者	Xu, Hua
作者单位	1.Univ Texas Hlth Sci Ctr Houston, Sch Biomed Informat, Houston, TX 77030 USA; 2.Chinese Acad Sci, Shanghai Inst Mat Med, Natl Ctr Drug Screening, Shanghai, Peoples R China; 3.Vanderbilt Univ, Dept Biomed Informat, Nashville, TN 37203 USA
推荐引用方式 GB/T 7714	Sun, Jingchun,Wei, Qiang,Zhou, Yubo,et al. A systematic analysis of FDA-approved anticancer drugs[J]. BMC SYSTEMS BIOLOGY,2017,11:27-43.
APA	Sun, Jingchun,Wei, Qiang,Zhou, Yubo,Wang, Jingqi,Liu, Qi,&Xu, Hua.(2017).A systematic analysis of FDA-approved anticancer drugs.BMC SYSTEMS BIOLOGY,11,27-43.
MLA	Sun, Jingchun,et al."A systematic analysis of FDA-approved anticancer drugs".BMC SYSTEMS BIOLOGY 11(2017):27-43.